These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 20720259

  • 1. Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects.
    Steinert RE, Poller B, Castelli MC, Drewe J, Beglinger C.
    Am J Clin Nutr; 2010 Oct; 92(4):810-7. PubMed ID: 20720259
    [Abstract] [Full Text] [Related]

  • 2. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men.
    Schmidt JB, Gregersen NT, Pedersen SD, Arentoft JL, Ritz C, Schwartz TW, Holst JJ, Astrup A, Sjödin A.
    Am J Physiol Endocrinol Metab; 2014 Jun 01; 306(11):E1248-56. PubMed ID: 24735885
    [Abstract] [Full Text] [Related]

  • 3. Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men.
    Steinert RE, Schirra J, Meyer-Gerspach AC, Kienle P, Fischer H, Schulte F, Goeke B, Beglinger C.
    Am J Clin Nutr; 2014 Aug 01; 100(2):514-23. PubMed ID: 24965303
    [Abstract] [Full Text] [Related]

  • 4. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.
    Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, Dakin CL, Filipsson K, Wang F, Kent AS, Frost GS, Ghatei MA, Bloom SR.
    Endocrinology; 2005 Dec 01; 146(12):5120-7. PubMed ID: 16150917
    [Abstract] [Full Text] [Related]

  • 5. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.
    Svane MS, Jørgensen NB, Bojsen-Møller KN, Dirksen C, Nielsen S, Kristiansen VB, Toräng S, Wewer Albrechtsen NJ, Rehfeld JF, Hartmann B, Madsbad S, Holst JJ.
    Int J Obes (Lond); 2016 Nov 01; 40(11):1699-1706. PubMed ID: 27434221
    [Abstract] [Full Text] [Related]

  • 6. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
    Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rössner S, Hellström PM.
    Int J Obes Relat Metab Disord; 1999 Mar 01; 23(3):304-11. PubMed ID: 10193877
    [Abstract] [Full Text] [Related]

  • 7. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects.
    Steinert RE, Poller B, Castelli MC, Friedman K, Huber AR, Drewe J, Beglinger C.
    Clin Pharmacol Ther; 2009 Dec 01; 86(6):644-50. PubMed ID: 19727071
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Intraduodenal infusion of a combination of tastants decreases food intake in humans.
    van Avesaat M, Troost FJ, Ripken D, Peters J, Hendriks HF, Masclee AA.
    Am J Clin Nutr; 2015 Oct 01; 102(4):729-35. PubMed ID: 26289437
    [Abstract] [Full Text] [Related]

  • 11. Irregular meal-pattern effects on energy expenditure, metabolism, and appetite regulation: a randomized controlled trial in healthy normal-weight women.
    Alhussain MH, Macdonald IA, Taylor MA.
    Am J Clin Nutr; 2016 Jul 01; 104(1):21-32. PubMed ID: 27305952
    [Abstract] [Full Text] [Related]

  • 12. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA, Horowitz M, Deacon CF, Feinle-Bisset C, Rayner CK, Luscombe-Marsh N, Little TJ.
    Am J Physiol Endocrinol Metab; 2014 Nov 01; 307(9):E830-7. PubMed ID: 25231186
    [Abstract] [Full Text] [Related]

  • 13. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.
    Näslund E, Gutniak M, Skogar S, Rössner S, Hellström PM.
    Am J Clin Nutr; 1998 Sep 01; 68(3):525-30. PubMed ID: 9734726
    [Abstract] [Full Text] [Related]

  • 14. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
    Lee A, Patrick P, Wishart J, Horowitz M, Morley JE.
    Diabetes Obes Metab; 2002 Sep 01; 4(5):329-35. PubMed ID: 12190996
    [Abstract] [Full Text] [Related]

  • 15. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.
    Field BC, Wren AM, Peters V, Baynes KC, Martin NM, Patterson M, Alsaraf S, Amber V, Wynne K, Ghatei MA, Bloom SR.
    Diabetes; 2010 Jul 01; 59(7):1635-9. PubMed ID: 20357366
    [Abstract] [Full Text] [Related]

  • 16. Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass.
    Fenske WK, Bueter M, Miras AD, Ghatei MA, Bloom SR, le Roux CW.
    Int J Obes (Lond); 2012 Mar 01; 36(3):379-84. PubMed ID: 21694700
    [Abstract] [Full Text] [Related]

  • 17. Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans.
    Melhorn SJ, Tyagi V, Smeraglio A, Roth CL, Schur EA.
    Appetite; 2014 Nov 01; 82():85-90. PubMed ID: 25049134
    [Abstract] [Full Text] [Related]

  • 18. Effect of peptide YY3-36 on food intake in humans.
    Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C.
    Gastroenterology; 2005 Nov 01; 129(5):1430-6. PubMed ID: 16285944
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.
    Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, Beglinger C.
    Am J Physiol; 1999 May 01; 276(5):R1541-4. PubMed ID: 10233049
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.